+91 789 2456 581 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
8 Sep 2019

GSK, INNOVAX and Xiamen University’s Global co-developmennt alliance for cervical cancer vaccine

/
Posted By
/
Comments0

INNOVAX, a subsidiary of China’s YangShengTang Group, and Xiamen University signed a global alliance partnership agreement on Friday with British pharmaceutical giant GlaxoSmithKline (GSK) in Wavre, Belgium, to develop a next-generation vaccine against human papillomavirus (HPV).

This is the first time a Chinese vaccine company, by leveraging its original technology, has entered into a partnership with a world leading vaccine company to co-develop and ultimately commercialize an important vaccine globally. This alliance shows that China’s vaccine technology has been highly regarded by its international counterparts. And the partnership is an exemplary collaboration between the pharmaceutical industries of China and Europe.

Under the agreement, INNOVAX will build a vaccine production line in Xiamen, southeast China, that will comply with the standards set by China, the United States, the European Union and the World Health Organization. It will produce and provide to GSK various types of HPV vaccine antigens, which will then be combined with GSK’s patented AS04 adjuvant to develop new HPV vaccines for worldwide commercialization, including in Europe and the United States.

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests 

etc.